title: [Negative regulatory factor of CAWS (Candida albicans water-soluble fraction) -vasculitis in CBA/J mice as assessed by comparison with Bruton's tyrosine kinase-deficient CBA/N mice].
abstract: Candida albicans water-soluble fraction (CAWS) has microbial pathogen-associated molecular patterns (PAMPs). It is a mannoprotein-β glucan complex obtained from the culture supernatant of Candida albicans NBRC1385 and exhibits vasculitis-inducing activity (CAWS vasculitis) in mice. The sensitivity to CAWS vasculitis varies greatly among mouse strains. This study examined the factors contributing to or inhibiting CAWS vasculitis using CAWS-vasculitis-resistant CBA/J mice and Bruton's tyrosine kinase (Btk)-deficient CBA/N mice, which is a CAWS-vasculitis-sensitive strain having the same origin as CBA/J mice. After stimulation with various kinds of pathogen-associated molecular patterns (PAMPs), the production of inflammatory cytokines IL-6 and IFN-γwas induced in CBA/N mice, whereas that of immunosuppressive IL-10 was induced in CAWS-vasculitis-resistant CBA/J mice. The production of TIMP1, an endogenous matrix metalloproteinase (MMP) inhibitor, was observed in CBA/J mice. Furthermore, the induction of CAWS-vasculitis was inhibited by gene therapy using plasmid (pCAGGS-mIL-10).  The results strongly suggest that the difference in the production of these cytokines is closely linked to the development of CAWS vasculitis.
authors.affiliation: Laboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences.
authors.forename: Noriko
authors.initials: N
authors.lastname: Nagi-Miura
mesh_terms: D000077329:Agammaglobulinaemia Tyrosine Kinase; D000818:Animals; D002176:Candida albicans / Q000378:metabolism / Q000472:pathogenicity*; D015316:Genetic Therapy; D007371:Interferon-gamma / Q000096:biosynthesis; D016753:Interleukin-10 / Q000235:genetics / Q000627:therapeutic use; D015850:Interleukin-6 / Q000096:biosynthesis; D008297:Male; D008562:Membrane Glycoproteins / Q000009:adverse effects* / Q000378:metabolism; D051379:Mice; D008808:Mice, Inbred CBA; D010957:Plasmids / Q000235:genetics; D011485:Protein Binding; D011505:Protein-Tyrosine Kinases / Q000172:deficiency*; D012995:Solubility; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000096:biosynthesis; D014657:Vasculitis / Q000209:etiology* / Q000378:metabolism / Q000382:microbiology / Q000628:therapy; D014867:Water; D047071:beta-Glucans / Q000009:adverse effects* / Q000378:metabolism
chemical_list: D015850:Interleukin-6; D008562:Membrane Glycoproteins; C560825:Timp1 protein, mouse; D019715:Tissue Inhibitor of Metalloproteinase-1; D047071:beta-Glucans; C025363:mannoproteins; D014867:Water; D016753:Interleukin-10; D007371:Interferon-gamma; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; C000625951:Btk protein, mouse